Clinico-biological features of patients with SMZL-T at transformation time point.
| Characteristic . | Total (%) . |
|---|---|
| Age >60 y | 24/36 (66.7) |
| Male/female | 14/27 (34.1/65.8) |
| B symptoms | 21/31 (67.7) |
| ECOG performance status ≥2 | 8/32 (25) |
| Ann Arbor stage III–IV | 28/32 (87.5) |
| Bulky disease (>7 cm) | 6/28 (21.4) |
| Hemoglobin < 100 g/L | 10/32 (31.3) |
| Platelets < 100 × 109/L | 5/32 (15.6) |
| Lactate dehydrogenase > UNL | 21/28 (75) |
| B2-microglobulin > UNL | 21/24 (87.5) |
| High–intermediate or high-risk IPI | 20/32 (62.5) |
| Complex karyotype | |
| Diagnosis | 6/12 (50) |
| Transformation | 7/11 (63.6) |
| del7q | |
| Diagnosis | 3/12 (25) |
| Transformation | 3/11 (27.3) |
| FISH at transformation | |
| BCL2 rearrangement | 0/15 (0) |
| BCL6 rearrangement | 2/20 (10) |
| MYC rearrangement | 1/23 (4.3) |
| Histological transformation | |
| At diagnosis | 5/36 (13.9) |
| During follow-up | 31/36 (86.1) |
| Median time to transformation (range), y | 2.42 (0-17) |
| Median time to treatment (range), y | 0.21 (0-11.7) |
| Characteristic . | Total (%) . |
|---|---|
| Age >60 y | 24/36 (66.7) |
| Male/female | 14/27 (34.1/65.8) |
| B symptoms | 21/31 (67.7) |
| ECOG performance status ≥2 | 8/32 (25) |
| Ann Arbor stage III–IV | 28/32 (87.5) |
| Bulky disease (>7 cm) | 6/28 (21.4) |
| Hemoglobin < 100 g/L | 10/32 (31.3) |
| Platelets < 100 × 109/L | 5/32 (15.6) |
| Lactate dehydrogenase > UNL | 21/28 (75) |
| B2-microglobulin > UNL | 21/24 (87.5) |
| High–intermediate or high-risk IPI | 20/32 (62.5) |
| Complex karyotype | |
| Diagnosis | 6/12 (50) |
| Transformation | 7/11 (63.6) |
| del7q | |
| Diagnosis | 3/12 (25) |
| Transformation | 3/11 (27.3) |
| FISH at transformation | |
| BCL2 rearrangement | 0/15 (0) |
| BCL6 rearrangement | 2/20 (10) |
| MYC rearrangement | 1/23 (4.3) |
| Histological transformation | |
| At diagnosis | 5/36 (13.9) |
| During follow-up | 31/36 (86.1) |
| Median time to transformation (range), y | 2.42 (0-17) |
| Median time to treatment (range), y | 0.21 (0-11.7) |
ECOG, Eastern Cooperative Oncology Group; UNL, upper normal limit.